Infectious Diseases Society Of America Inc, operating under the name Idsa, is located in Arlington, VA. The organization was established in 1970. According to its NTEE Classification (G03) the organization is classified as: Professional Societies & Associations, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. As of 12/2023, Idsa employed 123 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Idsa is a 501(c)(6) and as such, is described as a "Business League, Chambers of Commerce, or Real Estate Board" by the IRS.
For the year ending 12/2023, Idsa generated $37.6m in total revenue. This represents relatively stable growth, over the past 9 years the organization has increased revenue by an average of 6.1% each year. All expenses for the organization totaled $37.5m during the year ending 12/2023. While expenses have increased by 9.2% per year over the past 9 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2017, Idsa has awarded 23 individual grants totaling $3,761,192. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO PROMOTE EXCELLENCE IN THE PREVENTION AND CARE OF INFECTIOUS DISEASES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
IDWEEK ANNUAL CONFERENCE - IDWEEK 2023 IN BOSTON, MA, ATTRACTED A RECORD-BREAKING 12,000+ TOTAL ATTENDEES. THE MEETING IS THE WORLD'S PREMIER INFECTIOUS DISEASES EVENT. IDWEEK PROVIDES AN OPPORTUNITY FOR HEALTH PROFESSIONALS OF VARIED BACKGROUNDS TO LEARN FROM EACH OTHER'S KNOWLEDGE, EXPERIENCE AND EXPERTISE, FOR THE IMPROVEMENT OF PATIENT CARE AND PUBLIC HEALTH. THIS IS AN INCLUSIVE MEETING THAT OFFERS ACCESS TO INTERNATIONALLY RECOGNIZED LEADERS IN THE FIELD AND THE OPPORTUNITY TO NETWORK WITH THE MOST HIGHLY RESPECTED HEALTH PROFESSIONALS IN INFECTIOUS DISEASES, INCLUDING HIV.
CLINICAL INFECTIOUS DISEASES (CID), THE JOURNAL OF INFECTIOUS DISEASES (JID) AND OPEN FORUM INFECTIOUS DISEASES (OFID) ARE SCHOLARLY JOURNALS PUBLISHED BY IDSA IN PARTNERSHIP WITH AN OUTSIDE PUBLISHER TO DISSEMINATE THE LATEST RESEARCH ON A VARIETY OF TOPICS IN THE FIELD TO MEMBERS AND SUBSCRIBERS. CID PUBLISHES ORIGINAL RESEARCH, REVIEWS AND PERSPECTIVES THAT ALL CLINICIANS CAN USE WHEN CARING FOR PATIENTS. CID COVERS THE CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND PREVENTION OF THE FULL RANGE OF INFECTIOUS DISEASES. THE EVALUATION OF CURRENT AND NOVEL TREATMENTS, MICROBIOLOGY, IMMUNOLOGY AND POLICIES AS THEY RELATE TO PATIENT CARE ARE HIGHLY PRIORITIZED. PUBLISHED CONTINUOUSLY SINCE 1904, JID IS THE PREMIER GLOBAL JOURNAL FOR TRANSLATIONAL INFECTIOUS DISEASES SCIENCE. THE EDITORS WELCOME MAJOR ARTICLES AND BRIEF REPORTS DESCRIBING RESEARCH RESULTS ON MICROBIOLOGY, IMMUNOLOGY, EPIDEMIOLOGY, AND RELATED DISCIPLINES, ON THE PATHOGENESIS, DIAGNOSIS, AND TREATMENT OF INFECTIOUS DISEASES; ON THE MICROBES THAT CAUSE THEM; AND ON DISORDERS OF HOST IMMUNE RESPONSES. OFID PUBLISHES CLINICAL, TRANSLATIONAL AND BASIC RESEARCH IN A FULLY OPEN ACCESS, ONLINE JOURNAL. IT FOCUSES ON THE INTERSECTION OF BIOMEDICAL SCIENCE AND CLINICAL PRACTICE, WITH AN EMPHASIS ON KNOWLEDGE THAT COULD IMPROVE PATIENT CARE GLOBALLY. ARTICLES ARE WRITTEN BY EXPERTS IN THE FIELD, INCLUDING MEMBERS AND NON-MEMBERS, AND REVIEWED BY A PANEL OF LEADING MEDICAL EXPERTS BEFORE THEY ARE PUBLISHED.
IDSA WAS AWARDED A COOPERATIVE AGREEMENT TO SUPPORT THE CDC BY PROVIDING RESOURCES TO FRONTLINE HEALTH CARE PROFESSIONALS CARING FOR PATIENTS WITH COVID-19. THE PARTNERSHIP BRINGS NUMEROUS MEDICAL SPECIALTIES TOGETHER TO SHARE RESOURCES AND TO PROVIDE THE LATEST INFORMATION AND GUIDANCE ON TREATING THOSE INFECTED WITH COVID-19 AND PREVENTING ITS SPREAD. THROUGH FUNDING FROM CDC, IDSA EXPERTS SUPPORT CDC'S CLINICAL CALL LINES, PROVIDING GUIDANCE TO HEALTH CARE PROVIDERS TREATING COVID-19 PATIENTS. THE COLLABORATION HAS ALSO FUNDED THE FLOURISHING COVID-19 REAL-TIME LEARNING NETWORK, AN ONLINE CENTER FOR FRONTLINE CLINICIANS TO LEARN, COLLABORATE AND SHARE TREATMENT BEST PRACTICES. IDSA'S COVID-19 PRACTICE GUIDELINES ON DIAGNOSTICS, TREATMENT AND MANAGEMENT ALSO RECEIVE FUNDING THROUGH THE GRANT. ADDITIONALLY, UNDER THE PARTNERSHIP, TWICE-MONTHLY CLINICIAN TELECONFERENCES PROVIDE HEALTH CARE PROFESSIONALS ACCESS TO EXPERTS WITH THE LATEST INFORMATION ON THIS EVOLVING VIRUS AS WELL AS AN OPPORTUNITY TO ASK QUESTIONS. THE CALLS FREQUENTLY DRAW MORE THAN 800 ATTENDEES.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Christopher Busky Cae Chief Executive Officer | Officer | 36.5 | $571,440 |
Ty Johnson Chief Operating Officer | Officer | 25 | $291,719 |
Dana Wollins Svp, Strategy | Officer | 37.5 | $289,970 |
Amanda Jezek Svp, Policy & Gov. Relations | Officer | 37.5 | $286,139 |
Sandra Vura Hardwood Vp, Meetings And Education | Officer | 37.5 | $281,761 |
Felicity Clancy Vp, Marketing And Membership | 37.5 | $258,862 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Hart Health Strategies Consulting | 12/30/23 | $300,000 |
Beekeeper Group Llc Consulting | 12/30/23 | $189,000 |
Paul E Sax Md Consulting | 12/30/23 | $151,178 |
Sharon Stevens Consulting | 12/30/23 | $130,760 |
Marjorie Connolly Consulting | 12/30/23 | $122,760 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $3,137,684 |
All other contributions, gifts, grants, and similar amounts not included above | $307,401 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $3,445,085 |
Total Program Service Revenue | $31,529,250 |
Investment income | $1,333,605 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $471,013 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $673,334 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $37,618,238 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $250,000 |
Grants and other assistance to domestic individuals. | $286,081 |
Grants and other assistance to Foreign Orgs/Individuals | $415,324 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $2,206,963 |
Compensation of current officers, directors, key employees. | $0 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $10,298,111 |
Pension plan accruals and contributions | $421,618 |
Other employee benefits | $893,876 |
Payroll taxes | $834,458 |
Fees for services: Management | $0 |
Fees for services: Legal | $207,769 |
Fees for services: Accounting | $56,060 |
Fees for services: Lobbying | $538,340 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $146,014 |
Fees for services: Other | $9,557,738 |
Advertising and promotion | $568,893 |
Office expenses | $852,125 |
Information technology | $443,517 |
Royalties | $0 |
Occupancy | $826,825 |
Travel | $57,981 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $8,094,756 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $326,299 |
Insurance | $181,150 |
All other expenses | $0 |
Total functional expenses | $37,463,898 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $1,030,120 |
Savings and temporary cash investments | $1,685,037 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $3,501,022 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $745,103 |
Net Land, buildings, and equipment | $1,938,692 |
Investments—publicly traded securities | $46,913,163 |
Investments—other securities | $4,719,232 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $7,572,997 |
Total assets | $68,105,366 |
Accounts payable and accrued expenses | $2,772,658 |
Grants payable | $0 |
Deferred revenue | $4,312,114 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $9,193,344 |
Total liabilities | $16,278,116 |
Net assets without donor restrictions | $51,827,250 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $68,105,366 |
Over the last fiscal year, Infectious Diseases Society Of America Inc has awarded $650,000 in support to 5 organizations.
Grant Recipient | Amount |
---|---|
MONTEFIORE MEDICAL CENTER PURPOSE: LEAP AWARD | $100,000 |
UNIVERSITY OF MARYLAND PURPOSE: LEAP AWARD | $100,000 |
SEATTLE CHILDREN'S HOSPITAL PURPOSE: LEAP AWARD | $100,000 |
UNIVERSITY OF NEBRASKA CENTER PURPOSE: LEAP AWARD | $100,000 |
IDSA EDUCATION AND RESEARCH FOUNDATION PURPOSE: PROGRAM SERVICE ACCOMPLISHMENTS | $250,000 |